The European Biotech Act: Implications for Early Clinical Pharmacology and Phase 1 Industry in Europe and the UK

The European Union's proposed Biotech Act represents a strategic attempt to strengthen the region's health biotechnology sector by addressing systemic barriers that have limited competitiveness and innovation in recent decades. Despite Europe's strong scientific base, the EU has seen a decline in its global share of commercial clinical trials and insufficient venture capital mobilisation relative to competitors such as the United States and China [1]. Early clinical pharmacology, particularly Phase I and first‑in‑human (FIH) studies, stands at the nexus of innovation pathways, regulatory frameworks, and translational science. This article assesses how the proposed Biotech Act may influence this landscape, identifying potential benefits and missed opportunities.

Europe's Innovation Gap in Biotech and Early‑Phase Research

Europe's share of global biotechnology venture capital investment remains small, around 7%, and its share of commercial clinical trials has dropped from 22% to 12% over a decade [1]. Such trends reflect broader challenges: protracted regulatory timelines for clinical trial approvals, fragmented national requirements, and under‑capitalised ecosystems that drive early‑stage companies to relocate or expand outside the EU [2]. These dynamics have also affected the UK post‑Brexit, where regulatory autonomy offers both risk and opportunity for closer alignment with global frameworks.

The early clinical pharmacology environment, encompassing Phase I safety, tolerability, pharmacokinetics, and dose‑finding studies, depends heavily on efficient regulatory procedures, predictable timelines, risk‑proportionate oversight, and access to investment. The lack of harmonised, innovation‑friendly mechanisms hinders Europe's ability to attract first‑in‑human programmes compared with the relatively agile regulatory pathways seen in the UK, the US, or emerging hubs in Asia [3].

Key Objectives of the European Biotech Act

The European Commission's proposal for the Biotech Act is intended to create an integrated regulatory framework that enhances innovation and competitiveness across the biotechnology lifecycle, from early research through clinical development, manufacturing, and market access [4]. Key objectives include:

• Streamlining regulatory processes to reduce time‑to‑market for innovative therapies.
• Improving access to funding, especially for small and medium‑sized enterprises (SMEs) and high‑risk early-stage projects.
• Fostering the adoption of digital solutions, including artificial intelligence (AI) in trial design and execution.
• Coordinating across fragmented legislative frameworks, including clinical trials, advanced therapies, and biosecurity safeguards.
• Strengthening the regulatory and ethical framework for advanced therapy medicinal products and complex biologics [5].

These measures align with Europe's goal of retaining and building domestic capacity for health biotech innovation, particularly to mitigate the loss of talent and projects relocating abroad [1].

Potential Benefits for Early Clinical Pharmacology and Phase 1

Faster Regulatory Pathways and Trial Approval Timelines

One of the most tangible potential benefits of the Biotech Act is streamlined and more predictable clinical trial approval timelines. Proposals to cut average authorisation times to under 50 days, down from well over 100 days, would align EU clinical trial timelines more closely with leading jurisdictions and reduce administrative burdens for multinational early‑phase studies [6]. This could improve the attractiveness of Europe as a location for Phase I and FIH programmes, encouraging sponsors to retain or initiate early clinical studies within the EU.

Adapted regulatory sandboxes and risk‑proportionate requirements could also create more flexibility for novel modalities (e.g., advanced biologics, gene‑based therapies) that may otherwise face rigid interpretation under existing frameworks. In turn, this may support adaptive and innovative designs that are increasingly used in early clinical pharmacology to optimise dose selection and safety evaluation.

Boosting Access to Financing and Investment

The Biotech Act envisages a significant mobilisation of investment capital to support biotech scale‑up and innovation [4]. EU financial instruments, including collaboration with the European Investment Bank, are projected to allocate billions to reduce investment risks associated with early‑stage development [7]. Enhanced access to financing may fill critical gaps in late‑seed and Series A/B rounds, where European firms often struggle relative to US counterparts. This influx of capital could enable more clinical pharmacology programmes to reach Phase I readiness, with secure budgets and strategic partnerships.

Such support may also foster the growth of specialised contract research organisations (CROs) and Phase 1 units within Europe, creating innovation clusters with deep expertise in pharmacokinetics, modelling and simulation, and early translational science [8].

Use of AI and Digital Tools

A noteworthy aspect of the Commission's plans is the promotion of AI‑enabled clinical trials, which could cut costs and timelines by enhancing patient selection, data processing, and operational efficiencies [4]. In early clinical pharmacology, AI‑assisted modelling can support dose prediction, identification of safety signals, and integration of real‑world data, all of which contribute to improved decision quality in dose escalation and pharmacodynamic assessments [9].

The integration of digital platforms and interoperable data standards could also facilitate cross‑border Phase I trials, enabling sponsors to harmonise data across multiple regulatory environments using consistent analytical frameworks [10].

Improved Incentives for Biologics and Advanced Therapies

The Biotech Act's focus on health biotechnology strategic projects, including monoclonal antibodies, CAR‑T cell therapies, mRNA platforms, and other complex biologics, holds promise for early clinical pharmacology [5, 11]. By providing regulatory support, funding incentives, and extended intellectual property protections for qualifying products, Europe may retain and attract developers of cutting‑edge therapeutics that rely on robust early‑phase ecosystems.

These incentives could help level the playing field with other regions that have achieved success in advanced therapy development, thereby fostering translational programmes rooted in European institutions and clinical pharmacology expertise [12].

Opportunities Missed and Additional Considerations for the Biotech Act

Despite its potential, the Biotech Act also presents areas where opportunities may have been missed or under‑emphasised in its current draft:

Comprehensive Harmonisation Across All EU Member States

While the Act proposes central frameworks, full harmonisation across all Member States remains a challenge. Differences in national ethics committees, implementation of clinical trial oversight, and local interpretation of risk‑based requirements continue to create operational variability [13]. Without robust enforcement mechanisms and a truly unified pathway, sponsors may still encounter delays when navigating multi‑national Phase I programmes.

Specific Support for Academic and Investigator‑Initiated Trials

The Biotech Act emphasises commercial innovation and scale‑up, but it does not explicitly address the unique needs of academic and investigator‑initiated early clinical studies. These programmes often pioneer first‑in‑class science but lack the scale or financial power of industry sponsors [14]. Dedicated mechanisms to support academic sponsors, such as streamlined ethics approvals, dedicated grant funds, and regulatory assistance programmes, could have further strengthened the EU's early clinical ecosystem.

UK Inclusion and Post‑Brexit Alignment

The Act applies to the EU's 27 Member States, but the absence of explicit alignment mechanisms with the UK's regulatory framework (MHRA) represents a missed opportunity for broader European harmonisation. Given the UK's advanced regulatory initiatives aimed at innovation (e.g., adaptive pathways, early access schemes), stronger formal collaboration or mutual recognition agreements could enhance Phase I competitiveness across Europe's largest integrated market [15]. Although dialogue on mutual recognition of certain regulatory outcomes has been suggested by stakeholders, it is unclear how the Biotech Act will operationalise such alignment [6].

Explicit Provisions for Emerging Statistical and Trial Design Innovations

Modern clinical pharmacology increasingly incorporates adaptive, Bayesian, and model‑based trial designs to improve dose‑finding efficiency and real‑time learning. While the Biotech Act's provisions for AI and digitalisation are conducive to innovation, it does not explicitly codify regulatory support for such statistical designs,
which could be a powerful driver of early‑phase efficiency. Institutional guidance or regulatory frameworks that explicitly endorse these methods would give sponsors greater confidence to leverage innovative designs in Phase I studies.

Patient Engagement and Public Trust

The proposed Act lacks a strong, proactive framework for patient and public involvement in the early development of novel biotechnologies [16]. Building a transparent and participatory dialogue is crucial for addressing ethical concerns, ensuring societal acceptance, and designing trials that reflect patient needs, especially for sensitive FIH studies involving novel modalities like gene therapies.

Sustainability and Environmental Impact

As the biotech sector grows, so does its environmental footprint. The Act presents an opportunity to integrate "green lab" principles and sustainable manufacturing requirements into the innovation framework, promoting resource efficiency and circular economy models from early-stage development [17].

Implications for the UK

Although the Biotech Act is EU legislation, its impact will likely resonate in the UK regulatory and biotech sectors. The UK's MHRA is advancing innovation‑focused pathways (e.g., adaptive pathways, pre‑submission scientific engagement), which mirror Europe's goals for flexible regulation [4]. However, divergence in regulatory frameworks could create either fragmentation or complementary opportunities, depending on how alignment and data sharing evolve.

UK‑based sponsors may find advantages in maintaining parallel strategies: utilising a flexible UK pathway for early proof‑of‑concept and Phase I execution, while leveraging EU incentives and integrated markets for broader pan‑European trials under the Biotech Act. Greater cooperation between EMA and MHRA could amplify these opportunities [15].

Conclusion

The proposed European Biotech Act represents a landmark attempt to strengthen and future‑proof Europe's biotechnology innovation ecosystem, with potential benefits for early clinical pharmacology and the Phase I industry. Streamlined regulatory timelines, enhanced funding access, digital innovation incentives, and strategic support for advanced therapies collectively could improve Europe's attractiveness for early‑phase programmes. However, challenges remain: incomplete harmonisation, limited academic trial support, modest technical guidance on advanced statistical designs, insufficient provisions for patient engagement and sustainability, and the need for clearer EU—UK regulatory integration.

Maximising the Act's positive impact will require continued stakeholder engagement, agile implementation, and integration with complementary policies that support the entire clinical pharmacology value chain, from preclinical science to translational trials and beyond.

References

1. European Commission.Biotechnology - Public Health. Accessed Jan 2026.
2. The Pharmaceutical Industry in Figures – Key Data 2024. Brussels: EFPIA; 2024. Accessed Jan 2026.
3. Deloitte Centre for Health Solutions. The future of clinical trial regulation in Europe. London. Accessed Jan 2026.
4. European Commission.Commission proposes new measures to improve health and the healthcare sector. Press release. 2025 Dec 16. Accessed Jan 2026
5. EMA Guideline on Quality, non-clinical and clinical Requirements for Investigational Medicinal Products for Advanced Therapies in Clinical Trials. Accessed February 2025.
6. Coombs A. EU Biotech Act: Europe's plan to catch-up with the competition. Soc Chem Ind News. 2026 Jan. Accessed Jan 2026
7. European Commission and EIB Group announce new initiative to mobilise €10 billion investment for Europe’s biotech sector. Accessed Jan 2026.
8. Getz KA, Campo RA. New benchmarks for clinical trial performance. Ther Innov Regul Sci. 2018;52:22–28.
9. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477.
10. European Medicines Agency. Data Analysis and Real World Interrogation Network (DARWIN EU). [Internet]. Amsterdam: EMA; 2023. Accessed Jan 2026.
11. The Biotech Act will be divided into two phases. 2025. Accessed Jan 2026
12. EuropaBio response to the EU Biotech Act public consultation. Brussels: EuropaBio; 2025.Accessed Jan 2026.
13. Zemła-Pacud, Ż., Lenarczyk, G. Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer? IIC 54, 732–763 (2023).
14. Stolk P, Huiskes-Berends S, A landscape analysis for responsible transparency and clinical data disclosure for interventionalstudies in Europe and beyond. September 2024. Accessed Jan 2026
15. Clinical trials regulations: six-month countdown begins. Medicines and Healthcare products Regulatory Agency. MHRA; 2024 Accessed Jan 2026
16. Geissler J, Ryll B, di Priolo SL, Uhlenhopp M. Improving Patient Involvement in Medicines Research and Development: A Practical Roadmap. Ther Innov Regul Sci. 2017 Sep;51(5):612-619.
17. Urbina MA, Watts AJR, Reardon EE. Labs should cut plastic waste too. 2015;528(7583):479.